Companies: 10,795·Total market cap: $144.5T
ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc.

NDRANASDAQHealthcare● Active
$4.27
+$0.04(+0.95%)
Market Cap$3213734
P/E Ratio—
52W High$11.96
52W Low$2.96
Overview

ENDRA Life Sciences Inc. (NDRA) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

NDRA · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$762,365▼ -76.4% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$762,365
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
-76.4%
vs prior fiscal year
Latest Quarter
$356,462
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$762,365Cash on Hand
Total Debt$492,352Total Debt
Net Cash / Net Debt+$270,013Net Cash Position
Cash vs Debt Ratio
Cash 61%Debt 39%

ENDRA Life Sciences Inc. has a net cash position of $270,013, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$762,365 − $492,352 = +$270,013

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
NDRA annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$0.8M-76.4%
Dec 31, 2024$3.2M+14.0%
Dec 31, 2023$2.8M-42.0%
Dec 31, 2022$4.9M-48.3%
Dec 31, 2021$9.5M+30.9%
NDRA cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc.YOU
NDRA
$0.8M23.7%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

ENDRA Life Sciences Inc. (NDRA) cash on hand as of December 31, 2025 is $762,365, comprising $762,365 in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as ENDRA Life Sciences Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as ENDRA Life Sciences Inc. cash reserves or cash position.

ENDRA Life Sciences Inc. annual cash on hand history shows decreased -76.4% in 2025: decreased -76.4% in 2025. ENDRA Life Sciences Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

ENDRA Life Sciences Inc. carries total debt of $492,352 against cash of $762,365, resulting in a net cash position of +$270,013. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

NDRA cash on hand · 5 questions

As of December 31, 2025, ENDRA Life Sciences Inc. (NDRA) has $762,365 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $762,365 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $356,462. Data sourced from the annual 10-K filing via FMP.

NDRA cash on handNDRA cash reservesNDRA cash 2025how much cash does NDRA have

▸ Source: FMP /balance-sheet-statement · US GAAP · ENDRA Life Sciences Inc. · ENDRA Life Sciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025